NO855216L - Fremgangsmaate for fremstilling av tumor-nekrose-faktorer og relatert dna. - Google Patents

Fremgangsmaate for fremstilling av tumor-nekrose-faktorer og relatert dna.

Info

Publication number
NO855216L
NO855216L NO855216A NO855216A NO855216L NO 855216 L NO855216 L NO 855216L NO 855216 A NO855216 A NO 855216A NO 855216 A NO855216 A NO 855216A NO 855216 L NO855216 L NO 855216L
Authority
NO
Norway
Prior art keywords
tnf
procedure
tumor necrosis
necrosis factors
related dna
Prior art date
Application number
NO855216A
Other languages
English (en)
Norwegian (no)
Inventor
Walter C Fiers
Lucia M Fransen
Jan Honore Leo Tavernier
Anne Louise Marie Marmenout
Jose Van Der Heyden
Bernard Allet
Eric H Kawashima
Original Assignee
Biogen Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Nv filed Critical Biogen Nv
Publication of NO855216L publication Critical patent/NO855216L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO855216A 1984-12-21 1985-12-20 Fremgangsmaate for fremstilling av tumor-nekrose-faktorer og relatert dna. NO855216L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68459584A 1984-12-21 1984-12-21
US78584785A 1985-10-09 1985-10-09

Publications (1)

Publication Number Publication Date
NO855216L true NO855216L (no) 1986-06-23

Family

ID=27103367

Family Applications (1)

Application Number Title Priority Date Filing Date
NO855216A NO855216L (no) 1984-12-21 1985-12-20 Fremgangsmaate for fremstilling av tumor-nekrose-faktorer og relatert dna.

Country Status (16)

Country Link
US (1) US5487984A (de)
EP (3) EP0216786B1 (de)
JP (4) JP2557053B2 (de)
KR (1) KR940010865B1 (de)
AT (1) ATE73856T1 (de)
AU (2) AU601675B2 (de)
DE (1) DE3585690D1 (de)
DK (1) DK399786D0 (de)
ES (1) ES8705521A1 (de)
FI (1) FI86194C (de)
HU (1) HUT40702A (de)
IE (1) IE58709B1 (de)
NO (1) NO855216L (de)
NZ (1) NZ214711A (de)
PT (1) PT81754B (de)
WO (1) WO1986003751A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US5081021A (en) * 1986-02-04 1992-01-14 Mizuno Den Ichi DNA encoding HTNF variants exhibiting enhanced activity
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
EP0897987B1 (de) * 1989-10-24 2001-02-28 Chiron Corporation Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US6461851B1 (en) 1992-11-19 2002-10-08 Anticancer, Inc. High expression modules containing two or more tandem copies of a methioninase encoding sequence
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
US5715835A (en) * 1992-11-19 1998-02-10 Anticancer, Inc. Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
ES2184756T3 (es) * 1992-11-19 2003-04-16 Anticancer Inc Uso de metioninasa como agente antitumoral en quimioterapia antimetionina.
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
AU3818095A (en) * 1994-10-20 1996-05-15 Industrial Research Limited Separation of amino acids and peptides from protein hydrolysates
US6509170B1 (en) 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US7217788B2 (en) * 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
EP1362916A3 (de) * 1996-03-14 2004-02-18 Human Genome Sciences, Inc. Menschlicher Tumornekrosefaktor delta und epsilon
AU2003236393B2 (en) * 1996-03-14 2006-02-02 Human Genome Sciences, Inc. Methods of Treating or Preventing Inflammation or Rheumatoid Arthritis
AU761216B2 (en) * 1996-03-14 2003-05-29 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
CA2446734A1 (en) * 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20040229785A1 (en) * 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
JP2005132795A (ja) * 2003-10-31 2005-05-26 Genichiro Soma 抗悪性神経膠腫剤及び動物用抗悪性神経膠腫剤
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
US11111284B2 (en) * 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
CA2985816A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (de) 2015-08-28 2019-06-12 The General Hospital Corporation Agonistische anti-tumor-nekrosefaktorrezeptor-2-antikörper
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
CA3253342A1 (en) 2016-05-13 2026-03-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CA3109954A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
JP7652690B2 (ja) 2018-11-15 2025-03-27 ザ ジェネラル ホスピタル コーポレイション アゴニスト性腫瘍壊死因子受容体スーパーファミリーポリペプチド
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
NL7903195A (nl) 1979-04-24 1980-10-28 Philips Nv Inrichting voor kunstmatige nagalm.
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
FI811009L (fi) 1980-06-06 1981-12-07 Biogen Nv Foerbaettrade vektorer foerfaranden foer framstaellning av dessa vektorer och foer expression av klonade gener
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
WO1984001288A1 (fr) * 1982-10-06 1984-04-12 Takeshi Makitsubo Procede d'extraction du facteur de necrose de tumeur a partir d'un macrophage
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
DE3472793D1 (en) * 1983-12-26 1988-08-25 Asahi Chemical Ind A novel physiologically active polypeptide
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (de) * 1984-07-05 1985-11-26 Genentech Inc
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4677663A (en) * 1985-07-05 1987-06-30 Melita Electronic Labs, Inc. Telephone answering and call forwarding improvement
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5182196A (en) * 1985-10-09 1993-01-26 Biogen, Inc. Expression systems for overproduction of desired proteins

Also Published As

Publication number Publication date
PT81754A (en) 1986-01-02
AU601675B2 (en) 1990-09-20
IE58709B1 (en) 1993-11-03
WO1986003751A3 (en) 1986-08-14
KR860005023A (ko) 1986-07-16
JPH07213293A (ja) 1995-08-15
DK399786A (da) 1986-08-21
JP2548525B2 (ja) 1996-10-30
ES8705521A1 (es) 1987-05-01
ATE73856T1 (de) 1992-04-15
FI855130A0 (fi) 1985-12-20
WO1986003751A2 (en) 1986-07-03
EP0368367A1 (de) 1990-05-16
AU5301486A (en) 1986-07-22
JPS62501470A (ja) 1987-06-18
AU5510490A (en) 1990-10-25
EP0313104A2 (de) 1989-04-26
FI855130A7 (fi) 1986-06-22
NZ214711A (en) 1991-11-26
FI86194B (fi) 1992-04-15
JP2548526B2 (ja) 1996-10-30
FI86194C (fi) 1992-07-27
JP2548527B2 (ja) 1996-10-30
JP2557053B2 (ja) 1996-11-27
US5487984A (en) 1996-01-30
PT81754B (pt) 1987-12-30
EP0216786A1 (de) 1987-04-08
DK399786D0 (da) 1986-08-21
HUT40702A (en) 1987-01-28
KR940010865B1 (ko) 1994-11-18
EP0313104A3 (de) 1989-07-12
IE853273L (en) 1986-06-21
DE3585690D1 (de) 1992-04-23
JPH07213292A (ja) 1995-08-15
EP0216786B1 (de) 1992-03-18
ES550260A0 (es) 1987-05-01
JPH07213291A (ja) 1995-08-15

Similar Documents

Publication Publication Date Title
KR860005023A (ko) 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법
FR2603581B1 (fr) Procede pour isoler et purifier des aminoacides par chromatographie
FR2577217B1 (fr) Procede d'hydrogenation de l'acide acetique
AU580494B2 (en) Process for the extraction and purification of proteins from culture media producing them
AU2624788A (en) Method of purifying protein
RO92477A (ro) Procedeu de preparare pe cale microbiologica a l-carnitinei
DE3686738D1 (de) Verfahren zum herstellen von hochreinem niob.
ATE135366T1 (de) Verfahren zur reinigung von interleukin-4
DE3583245D1 (de) Herstellung von aminosaeuren durch biologischen austausch.
FR2552424B1 (fr) Procede de preparation de 1,1,1,3,3,3-hexafluoropropane-2-ol par hydrogenolyse de l'hydrate d'hexafluoroacetone
EP0209786A3 (en) Process for purifying human tumour necrosis factor
FR2552761B1 (fr) Procede de transformation directe d'un aldehyde en un ester ethylenique, nouvelles molecules synthetisees
FR2564828B1 (fr) Procede de preparation de n-(benzyloxycarbonyl) amino-acides possedant une fonction supplementaire
DK380785D0 (da) S-6-fluor-4-aminochroman-4-carboxylsyre-forbindelser og salte deraf, fremgangsmaade til fremstilling deraf og anvendelse deraf til fremstilling af sorbinil
FR2559778B1 (fr) Procede de preparation de cire punique
RO89760A2 (ro) Procedeu de obtinere a aminoacizilor
ZA859841B (en) Process for purifying tumor necrosis factors and for producing recombinant dna molecules coding for tumor necrosis factor-like compounds and tumor necrosis factors